<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459157</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12369 CohMSM-PrEP</org_study_id>
    <nct_id>NCT03459157</nct_id>
  </id_info>
  <brief_title>Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)</brief_title>
  <acronym>CohMSM-PrEP</acronym>
  <official_title>Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Expertise France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SESSTIM (IRD, Inserm, Université Aix-Marseille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coalition Internationale Sida, Pantin, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Médecine Tropicale, Anvers, Belgique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCAD-SIDA, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association African Solidarité, Ouagadougou, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche Internationale pour la Santé, Université de Ouagadougou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espace Confiance, Abidjan, Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espoir Vie Togo, Lomé, Togo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire BIOLIM, Université de Lomé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This demonstration project will assess the acceptability and feasibility of pre-exposure
      prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV
      prevention package in community-based clinics in West Africa.

      An interventional, open label, multidisciplinary and multicentre cohort study will be
      performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo.

      All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly
      clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or
      on-demand, according the participant's choice), immunisation against hepatitis B,
      individualised peer-led support (for adherence and prevention), group discussions, condoms,
      and lubricants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This demonstration project will assess the acceptability and feasibility of pre-exposure
      prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV
      prevention package in community-based clinics in West Africa.

      The specific objectives are to assess the acceptability of PrEP, the adherence to PrEP and to
      quarterly HIV testing, the safety of daily and on-demand use of TDF/FTC, the impact of PrEP
      on the other prevention strategies, the incidence of sexually transmitted infections (STIs)
      on PrEP, the &quot;real life&quot; effectiveness of PrEP use and treatment-related resistance, and the
      cost and cost-effectiveness of PrEP.

      This interventional, open label, multidisciplinary and multicentre cohort study will be
      performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo.

      All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly
      clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or
      on-demand, according the participant's choice), immunisation against hepatitis B,
      individualised peer-led support (for adherence and prevention), group discussions, condoms,
      and lubricants.

      These activities will be performed by community-based organisations which are pioneer in the
      fight against HIV, especially in MSM. The study will have a total duration of 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of MSM under PrEP among eligible HIV-seronegative participants</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of MSM using daily and/ord on-demand PrEP</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MSM followed after 3 years compared to the number of MSM included (retention in the program)</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of adherence reported by MSM</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Counting of TDF/FTC tablets</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of TDF and FTC</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV tests performed</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to quarterly HIV testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical and biological adverse events related to TDF and FTC</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the safety of daily and on-demand use of TDF/FTC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of condomless anal intercourse</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the evolution of the other prevention strategies on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of sexual intercourse associated with alcohol and/or drug use</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the evolution of the other prevention strategies on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of STIs</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the incidence of STIs on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of HIV infection</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the &quot;real life&quot; effectiveness of PrEP use and the emergence of treatment-related resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of TDF/FTC resistance among MSM newly infected by HIV</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the &quot;real life&quot; effectiveness of PrEP use and the emergence of treatment-related resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cost of the intervention over the study period and in the long term</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental cost-effectiveness ratio of the intervention (versus no intervention) over the study period and in the long term</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conditions of TDF/FTC price and of effectiveness for the intervention to be cost-effective in the study countries</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>HIV prevention package including PrEP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIV prevention package including PrEP</intervention_name>
    <description>All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.</description>
    <arm_group_label>HIV prevention package including PrEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male (or transgender male person at birth)

          -  At least 18 years old

          -  HIV-seronegative

          -  Having had at least one anal sex episode with another man within the previous 6 months

          -  Having at least one of the following criteria:

               -  Have a sexual partner (male or female) infected with HIV without evidence of
                  virological suppression

               -  Have had anal or vaginal sex episodes without condoms with more than one partner
                  within the previous 6 months

               -  Have had a sexually-transmitted infection (STI) within the previous 6 months
                  (syndromic or biological approach, or mentioned by the participant)

               -  Have received post-exposure prophylaxis for HIV within the previous 6 months

               -  Wishing to reinforce its means of prevention through the use of PrEP

          -  Accepting to participate in the study and signing the informed consent form

        Exclusion Criteria:

          -  Clinical manifestations suggesting a primary HIV infection

          -  Recent probable HIV exposure

          -  Creatinine clearance &lt;60 mL/min calculated according to the Cockroft &amp; Gault formula

          -  Positive or undetermined HBsAg

          -  Allergy or contraindication to any of the components of PrEP

          -  Participation in another biomedical and/or behavioral study on HIV or STIs (excluding
             CohMSM)

          -  Disability of the person making it difficult, if not impossible, to participate in the
             study or understanding of the information given to him

          -  Predictable non-compliance with the protocol (geographical distance, non-compliance
             with monitoring or other reasons)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Laurent, PhD</last_name>
    <phone>+33 4 67 41 61 50</phone>
    <email>christian.laurent@ird.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bintou Dembélé Keita, MD</last_name>
    <phone>+223 20 23 72 59</phone>
    <email>bdembele@arcadsida.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oasis, Association African Solidarité</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ter Tiero Elias Dah, MD</last_name>
      <phone>+ 226 71 35 86 35</phone>
      <email>tertiero81@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de Confiance, Espace Confiance</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Anoma, MD</last_name>
      <phone>+225 21 35 28 61</phone>
      <email>anomacamille@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique des Halles, ARCAD-SIDA</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bintou Dembélé Keita, MD</last_name>
      <phone>+223 20 23 72 59</phone>
      <email>bdembele@arcadsida.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Lucia, Espoir Vie Togo</name>
      <address>
        <city>Lomé</city>
        <country>Togo</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ephrem Mensah, MD</last_name>
      <phone>+228 90 01 64 11</phone>
      <email>ephremensah@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Mali</country>
    <country>Togo</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>Men who have sex with men</keyword>
  <keyword>Pre-exposure prophylaxis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

